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ABSTRACT 
 
  Skin fibrotic disorders such as systemic sclerosis (SSc) are characterized by an 
excessive production of extracellular matrix (ECM) and understood to develop under the 
influence of certain growth factors. Connective tissue growth factor (CTGF) is a 
cysteine-rich mitogenic peptide that is implicated in various fibrotic disorders and induced in 
fibroblasts after activation with transforming growth factor-β (TGF-β). To better understand 
the mechanisms of persistent fibrosis seen in SSc, we previously established an animal model 
of skin fibrosis induced by exogenous application of growth factors. In this model, TGF-β 
transiently induced subcutaneous fibrosis and serial injections of CTGF after TGF-β caused 
persistent fibrosis. To further define the mechanisms of skin fibrosis induced by TGF-β and 
CTGF in vivo, we investigated in this study, the effects of growth factors on the promoter 
activity of the proα2 (I) collagen (COL1A2) gene in skin fibrosis. For this purpose, we 
utilized transgenic reporter mice harboring the -17 kb promoter sequence of the mouse 
COL1A2 linked to either a firefly luciferase gene or a bacterial β-galactosidase gene. Serial 
injections of CTGF after TGF-β resulted in a sustained elevation of COL1A2 mRNA 
expression and promoter activity compared with consecutive injection of TGF-β alone on day 
8. We also demonstrated that the number of fibroblasts with activated COL1A2 transcription 
was increased by serial injections of CTGF after TGF-β in comparison with the injection of 
TGF-βalone. Furthermore, the serial injections recruited mast cells and macrophages. The 
number of mast cells reached a maximum on day 4 and remained relatively high up to day 8. 
In contrast to the kinetics of mast cells, the number of macrophages was increased on day 4 
and continued to rise during the subsequent consecutive CTGF injections until day 8. These 
results suggested that CTGF maintains TGF-β-induced skin fibrosis by sustaining COL1A2 
promoter activation and increasing the number of activated fibroblasts. The infiltrated mast 
cells and macrophages may also contribute to the maintenance of fibrosis.  
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INTRODUCTION 
 
Systemic sclerosis (SSc) is a multisystem disorder of connective tissue 
characterized by excessive fibrosis and vascular changes in the skin and various internal 
organs, with an autoimmune background. The central event in the pathogenesis of SSc is an 
abnormal accumulation of extracellular matrix (ECM) components, predominantly types I 
and III collagens. The mechanisms that cause excessive fibrosis in SSc remain incompletely 
understood. However, many studies have suggested that several growth factors and 
cytokines released from inflammatory cells, endothelial cells, fibroblasts, and other cells in 
the involved organs play an important role in the initiation and maintenance of connective 
tissue fibrosis (Jimenez et al., 1996) 
Among these factors, transforming growth factor-β (TGF-β) has gained much 
attention as an essential factor in the pathogenesis of SSc (Leroy et al., 1989), since TGF-β 
is a very potent stimulator of collagen synthesis by fibroblasts (Miles, 1987; Roberts and 
Sporn, 1993). However, studies have suggested that TGF-β expression at the fibrotic sites is 
limited to the early inflammatory stage in various fibrotic disorders in the skin, including 
SSc and localized scleroderma (Falanga et al., 1992; Higley et al., 1994). Furthermore, there 
is little difference in the ability to produce TGF-βbetween fibroblasts taken from SSc lesions 
and their normal counterparts (Needleman et al., 1990), thus implicating other growth 
factors as additional pathogenetic factors in the development of fibrosis in SSc.  
Connective tissue growth factor (CTGF) is a cysteine-rich peptide, originally 
identified in human umbilical endothelial cell supernatants that exhibit platelet-derived 
growth factor (PDGF)-like chemotactic and mitogenic activities toward mesenchymal cells, 
and appears to be antigenically related to PDGF A and B chain peptides (Bradham et al., 
1991). Because of its ability to induce the expression of ECM molecules as one of the 
mediators of TGF-β (Igarashi et al., 1993), CTGF has emerged as an additional candidate 
responsible for excessive production of ECM proteins in SSc (Takehara, 2000). Previously, 
CTGF expression was detected in vivo in many fibrotic diseases, including SSc, localized 
scleroderma, and keloid as well as in renal, hepatic, and lung fibrosis (Igarashi et al., 1995; 
Igarashi et al., 1996; Ito et al., 1998; Lasky et al., 1998; Paradis et al., 1999). In addition, 
Sato et al. reported that serum CTGF levels were increased in patients with SSc, and 
correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis (Sato et al., 
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2000).  
We recently established an animal model of skin fibrosis by exogenous injection of 
growth factors. In 1986, Roberts et al. reported that the subcutaneous injection of TGF-β in 
newborn mice caused granulation tissue formation followed by fibrosis (Roberts et al., 
1986). We conducted similar experiments, and found that TGF-β caused skin fibrosis after 3 
consecutive days of injection. However, this change was transient and disappeared after 7 
consecutive days of TGF-β injection (Shinozaki et al., 1997; Mori et al., 1999). In contrast, 
irreversible fibrosis was observed upon the simultaneous injection of TGF-β and CTGF or 
by the injection of TGF-β for the first 3 days followed by CTGF for the next 4 days. 
Irreversible fibrosis was not observed when TGF-β was injected after CTGF. These 
observations suggested that CTGF maintains skin fibrosis induced by TGF-β.  
Based on the results with TGF-β and CTGF described above, we hypothesized that 
a two-step process of fibrosis occurs in SSc (Takehara, 2003). We postulate that TGF-β 
induces fibrosis in the early stage of SSc, and then CTGF acts to maintain tissue fibrosis. To 
further define the mechanisms of skin fibrosis induced by TGF-β and CTGF in vivo, we 
investigated in this study, the effects of growth factors on the promoter the activity of proα2 
(I) collagen gene (COL1A2) in skin fibrosis by utilizing transgenic reporter mice harboring 
the COL1A2 gene upstream promoter sequence. We also examined the role of TGF-β and 
CTGF in inflammatory cell recruitment to the injection site in this animal model of skin 
fibrosis.  
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MATERIALS AND METHODS 
 
Transgenic mice 
All animals used in the present study received humane care in compliance with the 
guidelines of Kanazawa University School of Medicine. The transgenic mouse strains, 
GB17/3 and GB17/6, were kindly provided by Dr. B. de Crombrugghe, and contain the -17 
kb to +54 sequence of the mouse proα2 (I) collagen gene linked to either a firefly luciferase 
gene or a bacterial β-galactosidase gene (Bou-Gharios et al., 1996). Strong enhancer activity 
was observed between the –17 kb and –13.5 kb of the promoter (Bou-Gharios et al., 1996). 
The phenotype expression of these mice was normal and the general wound healing process 
was not impaired (Kinbara et al, 2002). We have previously confirmed that the expression 
levels of transgenes were similar between the two germlines of transgenic mice (Inagaki et 
al., 1998). In accordance with this, there was essentially no difference in the results of the 
following experiments between the two germlines. 
 
Growth factors   
Human recombinant TGF-β3 was kindly provided by Novartis Pharmaceutical Co. 
(Basel, Switzerland). Human recombinant CTGF was a generous gift from JT Industrial Co. 
(Tokyo, Japan). 
 
Experimental model 
TGF-β3 and CTGF were dissolved in phosphate-buffered saline (PBS), to obtain  
final concentrations of 40 and 20 ng/μl, respectively. Newborn mice were injected with 20 
μl of TGF-β3 (800 ng), CTGF (400 ng) or with PBS as a control into the neck subcutaneous 
tissue once a day for 3 or 7 consecutive days. Serial injections of the two growth factors 
(TGF-β3 for the first 3 days and CTGF for 4-7 days) were also conducted. The amounts of 
growth factors used in these experiments were previously shown to be optimal in our skin 
fibrotic animal models using BALB/C mice (Shinozaki et al., 1997; Mori et al., 1999).The 
mice were killed with an overdose of diethyl ether 24 hours after the final injection, and 
tissue samples were obtained from the site of injection. Parts of the tissue samples were 
fixed in 10% neutral buffered formalin and processed for routine histological examination 
and the measurement of collagen contents. The remaining tissue was embedded in 
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Tissue-Tek OCT compound (Miles, IN), snap frozen in liquid nitrogen, and stored at –70 OC 
prior to use. Ten serial 6-μm sections were cut from each frozen sample embedded in OCT 
compound. One section was used for X-gal staining and the remaining sections were 
subjected to RNA extraction. 
 
Measurement of collagen contents in tissue samples 
Tissue samples were embedded in paraffin and sections, approximately 15 μm 
thick, were obtained. Groups of 10 to 20 sections were deparaffinized after incubation with 
xylol, xylol:ethanol (1:1), ethanol, water:ethanol (1:1), and water. We used only granulated 
areas of the sections. Individual samples were placed in small test tubes and covered with 
0.2 ml of a saturated solution of picric acid in distilled water that contained 0.1 % Fast green 
FCF and 0.1 % Sirius red F3BA. The samples were rinsed several times with distilled water 
until the fluid was colorless. One milliter of 0.1 N NaOH in absolute methanol (1:1; v:v) 
was added and the eluted color was read in a spectrophotometer at 540 nm and 605 nm. The 
method is based on the selective binding of Sirius red F3BA and Fast green FCF to 
collagens and non-collagenous proteins, respectively (Lopez-De Leon and Rojkind, 1985). 
 
RNA isolation and cDNA synthesis 
Total RNA was extracted from frozen granulation tissue samples using RNeasy 
(Qiagen, Valencia, CA) spin columns, according to the manufacturer's protocol, with the 
addition of a DNase digestion step. RNA concentration and purity was determined 
spectrophotometrically by measuring fluorescence at 260 nM and 280 nM. Total RNA (100 
g) was reverse transcribed into cDNA in a total volume of 20 μ using a Reverse 
Transcription System (Promega, Madison, WI) according to the manufacturer’s instructions.  
 
Taqman quantitative real-time PCR analysis  
Four microliters was used as a template for real-time PCR, which was carried out 
in an ABI Prism 7000 Sequence Detector System (PE Applied Biosystems, Foster city, CA). 
The sequences of the mouseα2 chain of the type I collagen (COL1A2) primers and probe 
used are 5’-CAC CCC AGC GAA GAA CTC ATA-3’ (forward), 5’-GCC ACC ATT GAT 
AGT CTC TCC TAA C-3’(reverse) and 5’-CGC CCA GGC CAA CAA GCA TGT C-3’               
(probe). Intron-spanning primers were used to minimize the possibility of co-amplifying 
 7
genomic DNA. The primers for macrophage chemoattractant protein-1(MCP-1) were 
purchased from Applied Biosystems. We used the Taqman rodent GAPDH control reagent 
(PE Applied Biosystems) as an internal control. PCR (1 x (50 OC, 2 min, 95 OC, 10 min), 40 
x (95 OC, 15 sec, 60 OC, 1 min) was performed in the presence of 0.6 x Taqman Universal 
PCR master mix (PE Applied Biosystems), forward and reverse primers and a sequence- 
specific fluorescent probe. Optimal probe and primer concentrations were determined for 
each assay to ensure maximum specificity. Relative units (RU) were calculated by the 
comparative CT method. First, the CT for the target amplification (FAM) and the CT for the 
endogenous control (VIC; GAPDH) were determined for each sample. The Difference 
between the CT for the target and the CT for the internal control, called Δ CT, was calculated 
to normalize for the differences in the amounts of total nucleic acid added to each mixture. 
The Δ CT of the calibrator was subtracted from the Δ CT of each experimental sample to 
give ΔΔ CT . The amount of target normalized to an endogenous control and relative to the 
calibrator, was then calculated using the equation 2 (-ΔΔ CT). 
 
Luciferase assay   
The luciferase assay was performed as described previously (Kinbara et al., 2002). 
Briefly, granulation tissues were homogenized in a buffer containing 25 mM Tris (pH 7.8) 
and 2 mM DTT, and then subjected to three cycles of freezing and thawing. After 
centrifugation, the supernatant was assayed for luciferase activity in the presence of excess 
470 M D-luciferin, 2.67 mM MgSO4, 0.1 mM EDTA, 270 M CoA, and 530 M ATP 
using a luminometer (Microtech Nition, Funabashi, Japan). Luciferase activity was 
expressed as counts per minute per g tissue homogenate.  
 
β-galactosidase expression 
Granulation tissue blocks were cryo-sectioned 6 μm thick. Sections were fixed 
with 4 % paraformaldehyde at room temperature and subsequently stained with 0.1 % 
4-chloro-5-bromo-3 indolyl-β-galactoside (X-Gal) in 4 mM potassium ferricyanide, 4 mM 
potassium ferrocyanide, and 2 mM MgCl2 at 37 OC for 12-16 hrs. The sections were 
counterstained with eosin. The positively stained fibroblasts were counted in ten high power 
fields at x 400 (Bonnerot and Nicolas, 1993).  
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Histological examination and immunohistochemistory 
 The formalin-fixed and paraffin-embedded specimens were cut to a thickness  of 4 
μm and stained with hematoxylin and eosin or toluidine blue for mast cell staining. 
Immunohistochemical analysis using antimouse macrophage antibody (F4/80, clone A3-1, 
ACM, UK) at a dilution 1:100 was performed with biotinylated antimouse immunoglobulin 
G as secondary antibody. Visualization was done with the standard 
streptavidin-biotin-coupled immunoperoxidase technique (Histofine kit, Nichirei, Tokyo, 
Japan). The measurement of mast cells and macrophages was performed by averaging the 
number of cells identified by toluidine blue staining and positive for the F4/80 staining in 
nine high power fields (magnification, x 400), respectively.  
 
Statistical Analysis  
 Values were expressed as the mean ± SEM. Student’s t test was used to evaluate the 
statistical differences between the groups.  
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RESULTS 
 
Quantitative analysis of the amounts of collagen in an animal model of skin fibrosis 
induced by exogenous injection of TGF-β and CTGF 
 We previously showed that serial injections of CTGF after TGF-β caused 
persistent fibrotic tissue formation in newborn mice (Mori et al., 1999). In this experiment, 
we injected 800 ng of TGF-β on days 1-3 followed by 400 ng of CTGF on days 4-7. 
Histological examination revealed the formation of granulation tissue with fibrosis on day 4 
and this response became relatively weaker but persisted on day 14. Since the profibrogenic 
effects of TGF-β1, -β2,and -β were almost identical in previous experiments (Mori et al., 
1999), we used TGF-β (henceforth referred to as TGF-β) in all the experiments described 
in the present study. 
 To better understand the mechanisms of fibrosis induced by multiple cytokines in 
vivo, we first semi-quantified the amounts of collagen depositedin tissue samples obtained 
from this animal model of skin fibrosis. Collagen levels in the granulation tissue were 
significantly increased by TGF-βinjection on day 4 as compared with those in PBS-treated 
control mice and in CTGF-injected mice (Fig. 1A). After injecting TGF-β for seven 
consecutive days, a decrease in the collagen contents was found on day 8. In contrast, serial 
injections of CTGF after TGF-β caused a more prominent collagen accumulation than did 
TGF-β injection alone (Fig. 1B). These semi-quantitative results were for the most part 
consist ent with our previous histological findings.  
 We next compared the influence of the exogenous addition of TGF-β and CTGF on 
COL1A2 mRNA expression in fibroblasts. Figure 2 shows the expression levels of 
COL1A2 mRNA in granulation tissue determined by quantitative real-time PCR. TGF-β 
induced a significant increase in the amounts of COL1A2 mRNA on day 4 (Fig. 2A). The 
mRNA expression levels on day 8 after serial injections of CTGF and TGF-β  were 
relatively lower than those on day 4 after injection of TGF-β alone, but significantly higher 
than those on day 8 after the consecutive injection of TGF-β (Fig. 2B). Therefore, it is 
suggested that the serial injection of CTGF and TGF-β  is important to maintain a certain 
level of COL1A2 mRNA expression and cause persistent fibrosis.  
 
CTGF maintains the TGF-β-induced activation of COL1A2 promoter in vivo  
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 To confirm whether the increase in COL1A2 mRNA levels described above was 
attributed to the activation of COL1A2 transcription, we utilized transgenic reporter mice 
harboring the –17 kb enhancer and promoter sequence of the mouse COL1A2 linked to 
either a firefly luciferase or a bacterial β-galactosidase gene. We obtained tissue samples 
from the site of the injections on the indicated days and investigated the kinetics of 
luciferase activity, which represented the activity of the COL1A2 promoter in granulation 
tissue. As shown in Figure 3, the injection of TGF-β for 3 days resulted in a 6-fold increase 
in the luciferase activity on day 4 compared with the control (PBS injection). This activity 
returned to the control level after TGF-β for an addional 4 days. In contrast, sustained 
luciferase activity was observed until day 8 after the injection of TGF-βon days 1-3 followed 
by CTGF on days 4-7 (Fig. 3B).  CTGF injection alone for three days or for seven 
consecutive days did not increase the promoter activity. These results reflected the 
expression levels of COL1A2 mRNA determined by real-time PCR.    
 To investigate the numbers of fibroblasts in which the COL1A2 promoter was 
activated, we used X-gal staining to detect β-galactosidase expresion driven by the COL1A2 
enhancer and promoter. TGF-βinjections for 3 days increased the number of X-gal-positive 
fibroblasts compared with the control (Fig. 4A, B and E). In spite of additional TGF-β 
injections for 4 more days, the number of X-gal-positive fibroblasts was decreased 
dramatically to the control level (Fig. 4C). In contrast, serial injections of CTGF after 
TGF-β significantly increased the number of X-gal-positive fibroblasts on day 8 compared 
with the injection of TGF-β alone (Fig. 4D and F). Based on these findings, it is suggested 
that the persistent fibrosis induced by the cytokines in vivo resulted mostly from the 
sustained COL1A2 promoter activation and the increase in the number of activated 
fibroblasts.  
 
Profile of inflammatory cells in this animal model of skin fibrosis 
 It has been reported that numbers of mast cells and macrophages increase in 
fibrotic tissues (Nishioka et al., 1987; Ishikawa and Ishikawa, 1992). To test whether these 
inflammatory cells are associated with the progression of fibrosis in our model, we 
examined the numbers of mast cells and macrophages in fibrotic tissues. The number of 
mast cells was significantly increased after TGF-β injections for 3 days compared with the 
control (Fig 5). The number of mast cells returned to the basal level after TGF-β injections 
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for seven consecutive days. However, it persisted to show a relatively high level after serial 
injections of CTGF and TGF-β(Fig 5). TGF-β also increased the number of macrophages on 
day 4 (Fig 6). In contrast to the kinetics of mast cells, the number of macrophages continued 
to rise after subsequent CTGF injections on day 4-7 (Fig 6).  
 
Chemokine MCP-1 mRNA expression is elevated in an animal model of skin fibrosis 
 We found that mast cells and macrophages infiltrate skin in our animal model of 
skin fibrosis induced by exogenous injections of TGF-βand CTGF. To examine whether 
chemokines produced partly by inflammatory cells play a role in skin fibrosis, we 
performed real-time PCR analysis to determine the expression of MCP-1 mRNA in our 
animal model. On day 8, MCP-1 mRNA levels following serial injections of CTGF after 
TGF-β were elevated 8-times as much as those after the single injection of TGF-β or CTGF 
(Fig 7). 
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DISCUSSION 
  
TGF-β promotes fibroblast proliferation as well as matrix synthesis, and thus is 
generally considered to play a key role in the development of skin fibrotic disorders such as 
SSc (Leroy et al., 1989; Roberts and Sporn, 1993). The importance of TGF-β is also 
supported by animal models of scleroderma; treatment with anti-TGF-β antibodies was 
effective in preventing dermal sclerosis in the graft-versus-host disease (GVHD) 
scleroderma model (McCormick et al., 1999) and deletion of one TGF-β allele resulted in 
decreased dermal thickness in tight skin mice (McGaha et al., 2001). Our animal model of 
skin fibrosis further demonstrated that the injection of TGF-β was required for the initiation 
of skin fibrosis. However, a single application of TGF-β caused transient fibrosis, and was 
not sufficient to induce persistent fibrosis, even if applied for 7 consecutive days (Mori et al., 
1999). Furthermore, we conclusively found that the injection of CTGF after the initiation of 
fibrosis with TGF-β injection was necessary for developing persistent fibrosis (Mori et al., 
1999). Herein, we show that the persistent fibrosis induced by these cytokines in vivo is 
related to the sustained promoter activation of the gene for type I collagen, which is the 
most abundant component of the ECM in the skin. Our data also support that the increased 
number of fibroblasts with accelerated COL1A2 transcription contributes to maintaining 
fibrosis. 
 Type I collagen is the major structural component of the ECM and consequently, 
the main contributor to connective tissue physiology and pathology. The regulation of 
collagen expression by TGF-β appears to be controlled mostly at the level of transcription. 
Recent research demonstrated that TGF-β stimulation of COL1A2 promoter activity is 
mediated by synergistic cooperation between Sp1 and Smad3/Smad4, which are 
components of the TGF-β signaling pathways (Zhang et al., 2000). On the other hand, the 
role of CTGF in collagen expression remains controversial. The CTGF responsive element 
is localized between nucleotides –376 and +58 of the COL1A2 promoter and CTGF 
stimulates collagen synthesis transcriptionally in vitro (Shi-wen et al., 2000). However, 
Gore-Hyer et al. demonstrated that both normal and SSc fibroblasts showed no induction of 
collagen expression after stimulation with CTGF alone. They found that CTGF-mediated 
collagen synthesis requires the co-stimulatory activation of insulin signaling pathways 
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(Gore-Hyer et al., 2003). Our in vivo data also revealed that injection of CTGF alone did not 
stimulate COL1A2 promoter activity. However, serial injection of CTGF after TGF-β 
stimulated COL1A2 promoter activity. Thus, TGF-β may induce not only collagen synthesis, 
but also co-stimulatory molecules necessary for CTGF-mediated collagen expression. 
Another possible explanation is that CTGF can bind TGF-β directly through the 
cysteine-rich domain. Therefore this binding may enhance the activity of TGF-β to bind its 
receptor and potentiate the downstream signaling (Abreu et al., 2002).  
 Fibroblasts are heterogeneous in their capacity to synthesize a matrix (Jelaska et al., 
1996). Since TGF-β induces resistance to apoptosis in SSc fibroblasts, it may drive fibrosis 
in SSc by providing a survival advantage to clonal populations of high-collagen-producing 
fibroblasts (Jelaska and Korn, 2000). COL1A2-expressing fibroblasts can be easily detected 
in our transgenic mice using X-gal staining. This staining revealed that the number of 
fibroblasts with accelerated COL1A2 transcription was increased by the serial injection of 
CTGF after TGF-β compared with the injection of TGF-βalone. Therefore, CTGF may 
contribute to clonal selection by increasing the number of collagen-expressing fibroblasts.     
 Although we showed that injection of CTGF after TGF-β induced skin fibrosis in 
newborn mice, the precise mechanism of maintaining fibrosis is still unclear. Since the 
recruitment of inflammatory cells to the injection site releases a battery of cytokines and 
chemokines other than TGF-β and CTGF, these inflammatory cells such as mast cells and 
macrophages may contribute to the initiation or maintenance of skin fibrosis. Increased 
numbers of mast cells have been observed in SSc and hypertrophic scars (Kischer et al., 
1978; Hawkins et al., 1985; Nishioka et al., 1987). Further evidence has been obtained in a 
murine sclerodermatous graft-versus-host disease (GVHD) model for SSc. McCormick et al. 
showed that TGF-β1 mRNA up-regulation and mononuclear cell infiltration are observed by 
day 7 after bone marrow transplantation, preceding detectable increases in collagen mRNA 
and skin thickening (McCormick et al., 1999). They also demonstrated that antibodies to 
TGF-β prevent not only skin thickening and lung fibrosis, but also the infiltration and 
activation of mononuclear cells into skin (Zhang et al., 2002). Thus, the sustained number of 
mast cells and increased number of macrophages seen at the site of injection of CTGF 
following TGF-β may contribute to the maintenance of fibrosis via production of cytokines 
and chemokines.  
In this context, MCP-1 has become a topic of interest. MCP-1 belonging to the C-C 
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chemokine supergene family, has stimulatory effects on collagen expression via the 
up-regulation of TGF-β expression in addition to stimulating recruitment activities of 
monocyte/macrophages and lymphocytes (Gharaee-Kermani et al., 1996). Previous studies 
have demonstrated that MCP-1 gene expression increases in Bleomycin-induced pulmonary 
fibrosis(Zhang et al., 1994) or interstitial kidney fibrosis(Lloyd et al., 1997). Hasegawa et al 
showed that serum MCP-1 levels were significantly elevated in patients with SSc in 
comparison with normal controls(Hasegawa et al., 1999). A recent study showed that 
expression of MCP-1 in infiltrating mononuclear cells and fibroblasts in the lesional skin of 
SSc was increased(Yamamoto et al., 2001). These findings suggest that MCP-1 plays an 
important role in the pathogenesis of SSc. Our in vivo data also revealed that serial 
injections of CTGF after TGF-β increased MCP-1 mRNA expression levels. Thus, MCP-1 
might be a candidate for a co-stimulatory molecule necessary for CTGF-mediated induction 
of collagen synthesis our mouse fibrosis model. 
 TGF-β stimulates production of matrix proteins like collagen and inhibits that of 
matrix metalloproteinase. TGF-β also can induce the expression of other fibrotic cytokines 
such as CTGF, which leads to the proliferation of fibroblasts and further synthesis of matrix 
(Igarashi et al., 1993). However, consecutive injections of TGF-β alone down-regulated 
CTGF mRNA expression in fibroblasts in this model (Mori et al., 1999), and addition of 
CTGF was needed for persistent fibrosis. Since SSc fibroblasts constitutively express 
significant levels of CTGF (Shi-wen et al., 2000), abnormal persistence of CTGF gene 
expression may account for the excessive collagen synthesis seen in SSc. In addition to  
directly stimulating matrix gene expression, TGF-β is a very strong chemoattractant for 
mast cells, monocyte/macrophages and fibroblasts (Wahl et al., 1987; Gruber et al., 1994). 
These infiltrating cells responding to TGF-β also capable of producing TGF-β (Zhang 
et al., 2002), which may coordinate with chemokines in attracting more 
monocyte/macrophages and T cells to skin. Therefore, stimulatory signals released from 
these inflammatory cells may be necessary for CTGF-mediated collagen production in our 
animal model. In fact, inflammatory cells may contribute to the pathogenesis of SSc, as we 
previously showed that production of the profibrotic cytokine IL-13 by activated T-cells was 
increased in patients with SSc (Hasegawa et al., 1997). 
 Fibrosis is a complex process that may involve multiple cytokines and chemokines, 
which crosstalk with effector cells. Our animal model provides a unique opportunity to 
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further investigate these pathways in vivo, to better understand the mechanism of fibrosis 
and pathogenesis of SSc. For example, experiments with antibodies to these cytokines or to 
macrophage surface markers will be useful in preventing disease progression in SSc. 
Investigations of this nature are currently under way in our laboratory.  
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 LEGENDS 
 
Figure1. Semi-quantitative analysis of the amounts of collagen deposited in granulation 
tissues at 4 days (A) and 8 days (B) after injections. A: Newborn mice were injected with 20 
l of TGF-β3 (800 ng), CTGF (400 ng) or PBS as a control into subcutaneous tissue of the 
neck once a day for 3 consecutive days. Injection of TGF-β for 3 days significantly increased 
the collagen content of granulation tissues as compared with the control or CTGF alone. B: 
Newborn mice were serially injected with two growth factors or PBS as indicated. The 
collagen content of granulation tissue after serial injections of TGF-β for the first 3 days and 
CTGF for 4-7 days was significantly more than that after TGF-β injections for 3 days. Values 
are the mean of 5 mice in each group. *p<0.001 
 
Figure 2. mRNA expression levels of the α2 chain of the type I collagen in granulation 
tissues at 4 days (A) and 8 days (B) after injections. Total RNA was extracted from frozen 
tissue samples. The expression levels of COL1A2 mRNA were determined by real-time 
PCR and normalized against the GAPDH mRNA expression level in each sample. TGF-β 
significantly increased the expression of COL1A2 mRNA on day 4 (A), and serial injections 
of TGF-β and CTGF caused a persistent elevation of the mRNA expression on day 8 (B). 
Values are the mean of 5 mice in each group. *p<0.05. 
 
Figure 3. CTGF maintains the TGF-β-induced activation of the COL1A2 promoter in vivo. 
A: Newborn transgenic mice were injected with TGF-β3, CTGF or PBS as a control into 
subcutaneous tissue of the neck once a day for 3 or 7 consecutive days. In some cases, we 
injected CTGF for 4 days after injecting TGF-β for the first 3 days. Luciferase activity, 
which represents the activity of the proα2 (I) collagen promoter in granulation tissue, was 
determined on day 2, 4, 6, and 8 using a luminometer. Closed circles, squares and triangles 
express control, TGF-β and CTGF, respectively. Open triangles represent serial injections of 
CTGF after TGF-β. Luciferase activity of the TGF-βinjected mouse reached maximum on 
day 4 and returned to the control level on day 8. In contrast, a high level of COL1A2 
promoter activity was maintained after serial injections of TGF-β and CTGF. B: The bar 
graph shows the levels of COL1A2 promoter activity on day 8 following consecutive or 
serial injections. Serial injections of CTGF after TGF-β resulted in a 12-fold increase in the 
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luciferase activity on day 8 compared with consecutive injections of PBS or TGF-β. Values 
are the mean of 5 mice in each group. *p<0.01, **p<0.0001.  
 
Figure 4. Effects of TGF-β and CTGF on the numbers of X-gal-positive fibroblasts. Frozen 
tissue samples were stained with X-gal after the injection of PBS (A), TGF-β (B) or CTGF 
for 3consecutive days, TGF-β for 7 days (C), and CTGF for 4 days following TGF-β 
injections for the first 3 days (D). The sections were counterstained with eosin. The 
X-gal-stained fibroblasts were counted in ten high power fields at x 400. TGF-βinjection for 
3 days significantly increased the number of X-gal-positive fibroblasts compared with control 
on day 4 (E). Serial injections of CTGF after TGF-β further increased the number of 
X-gal-positive cells on day 8 (F). Values are the mean of 5 mice in each group. *p<0.01, 
**P<0.05. Original magnification; x400. 
 
Figure 5. Kinetics of mast cell recruitment in this animal model of skin fibrosis. We stained 
sections with toluidine blue for counting mast cells. The cells positive for toluidine blue were 
enumerated in three areas at x400 (A). Closed circles, squares and triangles express control, 
TGF-β and CTGF, respectively. Open triangles represent serial injections of CTGF after 
TGF-β. Note that the number of mast cells was significantly increased by TGF-β injections 
for 3 days compared with the control . Cell numbers remained relatively high on day 8 after 
serial injections of CTGF and TGF-β. Values are the mean of 5 mice in each group. 
*p<0.001, **p<0.005. Representative photographs are also shown; control (B), TGF-β for 3 
days (C), TGF-β for 7 days (D), and CTGF for 4 days after TGF-β for the first 3 days (E). 
Original magnification; x400. 
 
Figure 6. Kinetics of macrophage recruitment in this animal model of skin fibrosis. 
Immunohistochemical analysis using antimouse macrophage antibody (F4/80) diluted 1:100 
was performed with biotinylated antimouse immunoglobulin G as the secondary antibody. 
Visualization was done with the standard streptavidin-biotin-coupled immunoperoxidase 
technique. The positively stained cells were counted in ten high power fields at x400 (A). 
Closed circles, squares and triangles express control, TGF-β and CTGF, respectively. Open 
triangles represent serial injections of CTGF after TGF-β. Note that the number of 
macrophages was significantly increased by TGF-β injections for 3 days compared with 
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control. In addition, the number of macrophages continued to increase after additional CTGF 
injections for 4 days after the TGF-β injections. Values are the mean of 5 mice in each group. 
*p<0.05, **p<0.0005. Representative photographs are also shown; control (B), TGF-β for 3 
days (C), TGF-β for 7 days (D), and CTGF for 4 days after TGF-β for the first 3 days (E). 
Original magnification; x400. 
 
Figure 7. MCP-1 mRNA expression levels in granulation tissues on day 8. The levels of 
MCP-1 mRNA were determined by real-time PCR. Relative expression levels of MCP-1 
mRNA were normalized against those of GAPDH mRNA. Newborn mice were injected 
with TGF-β, CTGF or PBS once a day for 7 consecutive days or with serial injections of the 
two growth factors (TGF-β for the first 3 days and CTGF for 4-7 days). MCP-1 mRNA 
levels following serial injections of CTGF after TGF-β were 8-times as high as those after 
consecutive injections of TGF-β or CTGF. Values are the mean of 5 mice in each group. 
*p<0.05. 
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